SkinVision Achieves EU's Top Medical Device Certification, a Breakthrough for AI in Healthcare

Strategic Insights -

SkinVision, an AI-powered mobile app that detects skin cancer, has made history by becoming the first to receive Europe's top medical device certification, the MDR Class IIa. This achievement sends a powerful message that AI in healthcare can meet the highest standards for safety, effectiveness, and trust. The certification was granted after SkinVision proved its medical purpose: detecting skin cancer risk through photos taken by the user's mobile phone using the app.

With this milestone, SkinVision has raised the bar for medical-grade AI, paving the way for broader adoption in the healthcare system. The app has been certified as a medical device, proving its safety and reliability, and is no longer just a "health/wellness" app. The impact of this achievement will be felt by users and the healthcare industry, as it will make it easier for people to access early skin cancer detection and treatment, potentially saving thousands of lives.

Key Takeaways:

  • SkinVision has become the first AI-powered medical device to receive EU MDR Class IIa certification, the highest standard for medical devices in the EU.
  • The certification was granted after SkinVision proved its medical purpose: detecting skin cancer risk through photos taken by the user's mobile phone using the app.
  • The app has been certified as a medical device, proving its safety and reliability, and is no longer just a "health/wellness" app.
  • SkinVision has partnered with over 30 organizations worldwide, and is reimbursed for over 20 million people via insurers and employers.
  • Over 1.5 million individuals have unlimited free access to SkinVision through insurance plans, and individuals without these plans can download the app directly from the Apple App Store or Google Play Store for free.
  • SkinVision has a proven track record, having performed over six million skin checks for more than three million users worldwide.
  • The app empowers people to take control of their skin health, with a mission to reduce skin cancer-related deaths by 50 per cent and potentially save 250,000 lives in the coming decades.
  • The EU MDR Class IIa certification is recognized in several other markets that align with EU medical device regulations, including Australia, New Zealand, and the UK.

Statistics:

  • 33 per cent of large device makers are now 33 per cent less likely to launch in the EU first. [1]
  • 53 per cent of devices were previously classified as low-risk Class I, today 55 per cent are Class IIa. [2]
  • Roughly three-quarters of existing products will require costly reclassification by 2028. [2]
  • Over 20 million people are reimbursed for SkinVision via insurers and employers. [3]
  • Over 1.5 million individuals have unlimited free access to SkinVision through insurance plans. [3]
  • 255,000 users have been screened, and 1,374 clinically validated skin cancers have been detected. [4]

Sources:

  • MedTech Europe survey (2024) [1]
  • Peer-reviewed analysis of over 2,000 legacy software entries [2]
  • SkinVision press release [3]
  • Interview with Medicash [4]

References:

[1] MedTech Europe. (2024). "The impact of MDR on the medical device industry."

[2] MedTech Europe. (2024). "A peer-reviewed analysis of over 2,000 legacy software entries."

[3] SkinVision. (n.d.). "About Us."

[4] SkinVision. (n.d.). "Our Numbers."

[1] https://medtecheurope.org/

[2] https://medtecheurope.org/

[3] https://skinvision.com/

[4] https://skinvision.com/